Comparing the current results to its competitors, Day One Biopharmaceuticals Inc reported Revenue increase in the 4 quarter 2025 by 83.92 % year on year, while most of its competitors have experienced contraction in revenues by -2.27 %, achieved in the same quarter.
Day One Biopharmaceuticals Inc , despite income growth by most of its competitors recorded a net loss, despite income increase by most of its competitors of 2297.19 %
Day One Biopharmaceuticals Inc 's Comment on Competition and Industry Peers
The company operates in the pharmaceutical and biotechnology industry, which is characterized by rapid technological advancements and a focus on proprietary products. It competes with pharmaceutical and biotechnology companies, academic institutions, governmental agencies, and public and private research institutions. Competitors often possess greater financial resources, established market presence, and expertise in research and development, manufacturing, clinical testing, regulatory approvals, reimbursement, and marketing. Competition also extends to recruiting qualified personnel, establishing clinical trial sites, patient registration, and acquiring complementary technologies. Smaller or early-stage companies may be significant competitors, particularly through collaborations with larger companies. Future mergers and acquisitions may lead to increased resource concentration among competitors.
Due to outstanding performance in Overall company, revenue grew by 83.92 % Day One Biopharmaceuticals Inc improved its market share, to approximately 0.23 %.
April 23, 2024
This latest regulatory green light marks just the latest affirmation of Day One s ongoing commitment to revolutionizing the treatment paradigm in pediatric oncology. With gliomas accounting for nearly half of all central nervous system tumors in children, the approval of OJEMDA is set to herald a new era of hope for pediatric patients and their families grappling with this chronic health issue.Pediatric low-grade gliomas (pLGGs) are slow-growing tumors found in the brain and spinal cord. They account for roughly 30% of all childhood brain tumors, making them the most common type of central nervous system tumor in children. These tumors often displace or compress adjacent normal brain and neurologic tissue, l...
Publicly Traded Peers of Day One Biopharmaceuticals Inc
Kezar Life Sciences Inc Share Performance
-1.35%
Over The Past 5 Days
Kezar Life Sciences Inc
Profile
Kezar Life Sciences Inc is a biotechnology company that focuses on developing novel small molecule therapeutics. Their business model revolves around the discovery and development of innovative drugs to target autoimmune and inflammatory disorders, aiming to address unmet medical needs. They primarily operate by conducting extensive research and conducting clinical trials to deliver effective treatments for patients.
NextCure Inc is a biopharmaceutical company that operates with a unique business model. They focus on discovering and developing novel immunomedicines to treat various forms of cancer and other immune-related diseases. With a focus on developing innovative therapies that target immune cells, NextCure aims to provide effective and personalized treatment options for patients in need.
Panbela Therapeutics Inc is a biopharmaceutical company that focuses on developing innovative and effective treatments for pancreatic cancer. They aim to leverage their expertise in drug development and strategic partnerships to bring novel therapies to the market and address the unmet medical needs of patients with this devastating disease.
Sources:
Day One Biopharmaceuticals Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Day One Biopharmaceuticals Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
